Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.
A seven-amino-acid synthetic fragment related to the protein thymosin beta-4. Marketed for wound healing and sports recovery. Evidence is largely preclinical.
High demand in male fitness/recovery, frequently compared with BPC-157. It is scheduled for review at the FDA July 23, 2026 compounding advisory committee meeting.
| Claim | Strongest evidence |
|---|---|
| Wound healing | R Regulatory only |
| Tissue / sports recovery | C Animal |
| Injury repair | C Animal |
FDA staff reviewed a nominated lyophilized powder for injection, found no identified human administration data, and flagged injectable immunogenicity, aggregation, impurity, and characterization concerns. Staff proposed not adding TB-500.
No human safety/efficacy data identified by FDA. Injectable immunogenicity and impurity concerns. Anti-doping relevance makes athlete use hazardous.
It is a synthetic fragment related to thymosin beta-4, not the full protein.
No. FDA proposed not adding it to the compounding list and did not identify human administration data.
Choose your main interest, then get one email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.
Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.